Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.40 |
| ▸ | VHL | P40337 | 13/20 | 0.36 |
| ▸ | ELOC | Q15369 | 10/20 | 0.36 |
| ▸ | ELOB | Q15370 | 10/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26725347 | 0.88 | DPP4 (0.36) | DPP4DPP8DPP9VHLELOC | |
| SCHEMBL21759977 | 0.88 | VHL (0.38) | DPP4DPP8DPP9VHLELOC | |
| SCHEMBL24558588 | 0.87 | DPP4 (0.36) | DPP4DPP8DPP9VHLELOC | |
| SCHEMBL24239716 | 0.86 | DPP4 (0.35) | DPP4DPP8DPP9VHLELOC | |
| SCHEMBL22138839 | 0.86 | VHL (0.41) | DPP4DPP8DPP9VHLELOC | |
| SCHEMBL22959576 | 0.85 | VHL (0.46) | DPP4DPP8DPP9VHLELOC | |
| SCHEMBL23651723 | 0.85 | VHL (0.46) | DPP4DPP8DPP9VHLELOC | |
| SCHEMBL23183583 | 0.83 | VHL (0.41) | DPP4DPP8DPP9VHLELOC | |
| SCHEMBL21554505 | 0.83 | VHL (0.41) | DPP4DPP8DPP9VHLELOC | |
| SCHEMBL21554539 | 0.83 | VHL (0.41) | DPP4DPP8DPP9VHLELOC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200199247-A1 | ANTIBODY CONJUGATES OF IMMUNE-MODULATORY COMPOUNDS AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199247-A1 | ANTIBODY CONJUGATES OF IMMUNE-MODULATORY COMPOUNDS AND USES THEREOF | LTK, TGFBR2, TNIK | DPP4 3570/4885DPP8 2878/4885DPP9 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.